Companies › Hunan Kelun Pharmaceutical
4 active drug programs in 4 registered trials: 4 Phase 1; Other; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| KL0011034 injection | – | Phase 1 | Healthy Volunteers | Dec 2027 |
| KLA318-2 Nanocrystal Injection | – | Phase 1 | Healthy Participants | – |
| KLA478 | – | Phase 1 | Healthy Volunteers | – |
| KLA578-1 for injection | – | Phase 1 | Healthy Volunteers | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07143318 | KLA578-1 for injection | Phase 1 | Healthy Volunteers | Other | May 2026 |
| NCT07171034 | KLA318-2 Nanocrystal Injection | Phase 1 | Healthy Participants | Other | May 2026 |
| NCT07240675 | KLA478 | Phase 1 | Healthy Volunteers | Other | Sep 2026 |
| NCT07474545 | KL0011034 injection | Phase 1 | Healthy Volunteers | Other | Dec 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.